Results 11 to 20 of about 1,751 (155)

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary [PDF]

Journal of Comparative Effectiveness Research
What is this summary about? This is a plain language summary of a published article in the journal Sleep. Narcolepsy is a sleep condition that has 2 different subtypes: narcolepsy type 1 and narcolepsy type 2. These are called NT1 and NT2 for short.
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Fèri Ascencion, Jennifer Gudeman   +6 more
doaj   +2 more sources

Endogenous Levels, Detection Time, and Symptoms of Gamma-Hydroxybutyric Acid: Results From a Placebo-Controlled Clinical Trial. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Gamma‐hydroxybutyric acid (GHB), a potential agent in drug‐facilitated sexual assault, is difficult to detect due to rapid elimination, endogenous presence, and possible postsampling formation. We conducted a randomised, placebo‐controlled trial in 30 healthy volunteers, administering 50‐mg/kg sodium oxybate or placebo, to investigate symptoms,
Faldborg KB, Sørensen LK, Hasselstrøm JB, Andersen CU.   +3 more
europepmc   +2 more sources

Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study

Sleep Medicine, 2023
The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB).TENOR is a patient-centric, prospective, observational, virtual-format ...
Charles J, Bae, Phyllis C, Zee, Eileen B, Leary, Douglas S, Fuller, Wayne, Macfadden, Shawn, Candler, Teresa L, Steininger, Aatif M, Husain   +7 more
openaire   +2 more sources

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

Neurology and Therapy, 2023
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg, Rogelio Braceras, Wayne Macfadden, Shawn Candler, Jed Black, Chad Ruoff   +5 more
doaj   +1 more source

Sodium Oxybate: a Substitute for Alcohol?

European Psychiatry, 2022
Gamma-hydroxybutyrate (GHB) is a neurotransmitter found naturally in the human brain. Sodium oxybate (SO) is the sodium salt of GHB. In 2000 GHB was classified a Schedule I controlled substance, while SO became a Schedule III controlled substance for ...
A. Gual, H. López-Pelayo, P. Bruguera, L. Miquel   +3 more
doaj   +1 more source

Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options [PDF]

, 2020
Fibromyalgia, characterised by persistent pain, sleep disturbance, fatigue and cognitive dysfunction, is a central sensitivity syndrome that also involves abnormality in peripheral generators and in the hypothalamic pituitary adrenal axis.
Lawson, Kim
core   +1 more source

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review. [PDF]

Brain Behav
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Hastings NE, Abdi KE, Bibi F, Aslam B, Nuñez MR, Sherani MTR, Shadmani S, Alam U, Hassan VM, Hoor-E-Ainaa, Imran H, Hanna J, Sadat SH.   +12 more
europepmc   +2 more sources

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications [PDF]

, 2022
Correction:Background Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium.
Black, Jed, Bogan, Richard K., Chen, Abby, Dauvilliers, Yves, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Partinen, Markku, Skobieranda, Franck, Skowronski, Roman, Sonka, Karel, Thorpy, Michael J.   +10 more
core   +2 more sources

Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home : an exploratory study [PDF]

, 2013
Background: Gamma-hydroxybutyric acid (GHB), well known as a party drug, especially in Europe, is also legally used (sodium oxybate, Xyrem (R)) to treat a rare sleep disorder, narcolepsy with cataplexy.
Hertegonne, Katrien, Ingels, Ann-Sofie, Lambert, Willy, Stove, Christophe   +3 more
core   +1 more source